Allergan ( AGN - Get Report), the California-based global health care company, said on Monday that antitrust authorities in Germany and Spain have cleared its acquisition of Inamed ( IMDC).

The deal is still waiting for clearance from the U.S. Federal Trade Commission. Allergan said in a press release that both the companies are working with the FTC to complete divestiture of Inamed's license for Reloxin to facilitate antitrust approval.

Botox-maker Allergan in December signed a definitive agreement to buy Inamed, a maker of breast implants and dermatology treatments. Allergan will pay $84 in cash, or 0.8498 of a share, for each Inamed share.

This story was created through a joint venture between TheStreet.com and IRIS.